NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
1720
[Article]
Center for Virology and Vaccine Research
3 Blackfan Circle
Boston, MA 02115 – USA
T 617.667.7000
F 617.735.4566
E CVVRcontact@bidmc.harvard.edu
CVVR Clinical Trials Unit
T 617.735.4610
E CVVRtrials@bidmc.harvard.edu
[DISPLAY_ULTIMATE_SOCIAL_ICONS]